Literature DB >> 10359087

Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89.

S Ye1, C Whatling, H Watkins, A Henney.   

Abstract

Matrix metalloproteinase expression is under strict regulation in physiological conditions. Disruption of the regulatory mechanisms can lead to tissue destruction and is associated with tumour invasion and metastasis. Using the one-hybrid assay technique with a cis-element in the promoter region of the stromelysin (matrix metalloproteinase-3) gene, a cDNA encoding a transcription factor termed ZBP-89 was obtained. The interaction between ZBP-89 and the stromelysin promoter element was confirmed by electrophoretic mobility shift assays with a recombinant ZBP-89. Reporter gene expression under the control of the stromelysin promoter in transiently transfected cells was significantly increased when the cells were cotransfected with a ZBP-89 expression construct. These results indicate that ZBP-89 interacts with the stromelysin promoter and upregulates its activity. As ZBP-89 expression is known to be increased in gastric carcinoma cells, induction of stromelysin expression may be a significant factor in tumour metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359087     DOI: 10.1016/s0014-5793(99)00509-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes.

Authors:  Masahiko Kure; Marcus G Pezzolesi; G David Poznik; Pisut Katavetin; Jan Skupien; Jonathon S Dunn; Josyf C Mychaleckyj; James H Warram; Andrzej S Krolewski
Journal:  Mol Genet Metab       Date:  2011-01-14       Impact factor: 4.797

2.  The Epstein-Barr virus protein BMRF1 activates gastrin transcription.

Authors:  Elizabeth A Holley-Guthrie; William T Seaman; Prasanna Bhende; Juanita L Merchant; Shannon C Kenney
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer.

Authors:  Longchuan Bai; Craig Logsdon; Juanita L Merchant
Journal:  Int J Gastrointest Cancer       Date:  2002

4.  Expression of transcription factor zinc-binding protein-89 (ZBP-89) is inhibited by inflammatory cytokines.

Authors:  Ruth C Borghaei; Mariah Chambers
Journal:  Pathol Lab Med Int       Date:  2009-08-01

5.  A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas.

Authors:  C De Bustos; A Smits; B Strömberg; V P Collins; M Nistér; G Afink
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

6.  Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study.

Authors:  Imen Guizani; Wiem Zidi; Yosra Zayani; Fourti Nesrine; Hayet Douik; Haifa Sanhaji; Mohamed Sami Mourali; Moncef Feki; Monia Allal-Elasmi
Journal:  Mol Biol Rep       Date:  2022-08-12       Impact factor: 2.742

7.  Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program.

Authors:  Morgan Salmon; Gary K Owens; Zendra E Zehner
Journal:  Biochim Biophys Acta       Date:  2009-02-14

8.  NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter.

Authors:  Ruth C Borghaei; Grzegorz Gorski; Masoud Javadi
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

9.  ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator, Sp1.

Authors:  Xueping Zhang; Iman H Diab; Zendra E Zehner
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

10.  The transcriptional repressor ZBP-89 and the lack of Sp1/Sp3, c-Jun and Stat3 are important for the down-regulation of the vimentin gene during C2C12 myogenesis.

Authors:  Morgan Salmon; Zendra E Zehner
Journal:  Differentiation       Date:  2009-02-23       Impact factor: 3.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.